Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

Vanda Pharmaceuticals (NASDAQ:VNDA) reported first-quarter 2026 revenue of $51.7 million, a 3% increase from $50.0 million in the prior-year period, as growth in Fanapt was partially offset by ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

Shares of Vanda Pharmaceuticals (VNDA) have gained 8.5% over the past four weeks to close the last trading session at $7.56, ...

WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective ...

In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt ...

Preview this article 1 min It's the first new prescription medication for the condition in more than four decades and comes ...

WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a ...

This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they ...

The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...